

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 July 2021 (08.07.2021)



(10) International Publication Number
WO 2021/138474 A2

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2020/067543

(22) International Filing Date:
30 December 2020 (30.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/957,024 03 January 2020 (03.01.2020) US
63/070,596 26 August 2020 (26.08.2020) US

(71) Applicant: MARENGO THERAPEUTICS, INC.
[US/US]; 840 Memorial Drive, 4th Floor, Cambridge,
Massachusetts 02139 (US).

(72) Inventors: TAN, Seng-Lai; 840 Memorial Drive, 4th
Floor, Cambridge, Massachusetts 02139 (US). VASH, Brian
Edward; 840 Memorial Drive, 4th Floor, Cambridge,
Massachusetts 02139 (US). HSU, Jonathan; 840 Memorial
Drive, 4th Floor, Cambridge, Massachusetts 02139
(US). GUNASEKERA, Dilini Charmain; 840 Memorial
Drive, 4th Floor, Cambridge, Massachusetts 02139 (US).
PALAKURTHI, Sangeetha Sagar; 840 Memorial Drive,
4th Floor, Cambridge, Massachusetts 02139 (US). LOEW,
Andreas; 840 Memorial Drive, 4th Floor, Cambridge,
Massachusetts 02139 (US). KATRAGADDA, Madan;
840 Memorial Drive, 4th Floor, Cambridge, Massachusetts
02139 (US). MAREK, Peter; 840 Memorial Drive, 4th
Floor, Cambridge, Massachusetts 02139 (US). GUNTAS,
Gurkan; 840 Memorial Drive, 4th Floor, Cambridge, Mass-
achusetts 02139 (US).

(74) Agent: WANG, Yingjiao; WILSON SONSINI
GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto,
California 94304 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(54) Title: ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF

(57) Abstract: The disclosure provides antibody molecules that bind
to TCR V β regions and multispecific molecules comprising said an-
tibody molecules. Additionally, disclosed are nucleic acids encoding
the same, methods of producing the aforesaid molecules, pharma-
ceutical compositions comprising aforesaid molecules, and methods
of treating a cancer using the aforesaid molecules.




FIG. 108C

WO 2021/138474 A2